

GLUCOMETRIX^{AG}

PRESS RELEASE

GlucoMetrix AG successfully completes the development of a manufacturing process for recombinant human insulin.

With this new manufacturing process insulin can be produced at lower cost in comparison with traditional methods. Starting signal for the production for the clinical phase is 2010.

Ruhpolding / Potsdam, 2nd of October 2009.

GlucoMetrix AG, founded in Upper Bavaria, Ruhpolding has successfully completed the development of a procedure for the extraction of recombinant human insulin. "On the basis of cell tests, we have demonstrated that we produce active insulin", said Peter-Paul Schikora, CEO of GlucoMetrix AG. "This is very good news not only for our company but also for millions of diabetics worldwide."

As early as 2010, the launch of the production for the clinical phase shall take place. "With the currently provided set of two kilograms of insulin we will be able to provide insulin for up to 2000 patients in the clinical phase", said Peter-Paul Schikora.

On the way to market readiness the company GlucoMetrix AG is currently, in cooperation with a contract manufacturer, trying to transfer its method of the constructed expression system and manufacturing process for human insulin into production scale. The optimization of growth conditions will be researched further in order to realize additional cost savings in this area.

The human insulin produced with GlucoMetrix's manufacturing process will be tolerated much better and is less expensive than other insulins previously available on the market. On the company's research site, in the Science Park Golm near Potsdam, the researchers have also found an optimal combination of an expression vector and host cell. This modern expression system promises high production yields at low cost.

The GlucoMetrix insulin is not produced from animal cells. Furthermore it is no analogue insulin, but the human hormone that is produced according to pharmaceutical biotechnology. For the insulin-dependent patients this means, that the current debate about increased cancer rates for analogue insulin does not apply to this product. Thanks to modern pharmaceutical chemistry and nanotechnology innovative

formulations – meaning the preparation of insulin to be injected into the human body – can be found. Through suitable formulations, GlucoMetrix AG will be able to produce, both a short-term and a long-term insulin for the different needs of the different diabetes mellitus types.

Insulin is a vital hormone for humans. Its main function is the regulation of the concentration of glucose in the blood. Insulin is produced in the pancreas. The pancreas in this context is responsible for the biosynthesis, storage and release of the hormone. The global need for insulin is currently growing at a fast pace. Due to the exorbitantly rapidly progressing cross border spread of the metabolic disease diabetes mellitus, insulin is narrow and expensive. The current annual production volume is at six tons. Already in 2012, experts anticipate a global demand of 16 tonnes. GlucoMetrix AG wants to produce about three tons annually of its own human insulin.

Diabetes mellitus is a metabolic disease, with an impaired uptake of glucose from the blood into the cells and thus the blood sugar is elevated. People affected, must regulate their blood glucose levels with injectable insulin. According to current estimates by the International Diabetes Federation, nearly 250 million people worldwide suffer from diabetes. Currently, Germany stands at just under 8 million diabetics in 5th place in international comparison.

The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-aftermath. At the foreground of research and development is the enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sustainably.

For inquiries please contact:

Heiner Sieger
Economic and Financial Editors Munich
Zugspitzstrasse 140
D-85591 Stetten
+49 163 723 723 0
heiner.sieger@redaktionmuenchen.com
hsieger@glucometrix.de